950 Panoramica delle azioni Lee's Pharmaceutical Holdings Limited, una holding di investimento, sviluppa, produce, commercializza e vende prodotti farmaceutici principalmente nella Repubblica Popolare Cinese. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Lee's Pharmaceutical Holdings Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Lee's Pharmaceutical Holdings Prezzi storici delle azioni Prezzo attuale dell'azione HK$1.45 Massimo di 52 settimane HK$1.60 Minimo di 52 settimane HK$1.00 Beta 0.85 Variazione di 1 mese 21.85% Variazione a 3 mesi 14.17% Variazione di 1 anno -5.23% Variazione a 3 anni -56.72% Variazione a 5 anni -68.41% Variazione dall'IPO 178.85%
Notizie e aggiornamenti recenti Vedi altri aggiornamenti
Investor sentiment improves as stock rises 16% Dec 12
Investor sentiment improves as stock rises 16% Oct 02
Board Member recently bought HK$66k worth of stock Sep 22
Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem Sep 04
First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023) Sep 03
First half dividend of HK$0.02 announced Aug 30
Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price Aug 07
Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong Aug 02
Board Member recently bought HK$59k worth of stock Jul 17
Board Member recently bought HK$117k worth of stock Jul 07
Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director Jul 02
Board Member recently bought HK$120k worth of stock Jun 21
Board Member recently bought HK$61k worth of stock Jun 15
Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01 May 21
Upcoming dividend of HK$0.01 per share May 21
Board Member recently bought HK$130k worth of stock May 10
Less than half of directors are independent Apr 22
Final dividend of HK$0.01 announced Mar 28
Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024 Mar 27
Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022) Mar 27
Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024 Mar 26
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 15
Board Member recently bought HK$123k worth of stock Jan 25
New minor risk - Market cap size Jan 17
Board Member recently bought HK$75k worth of stock Jan 17
Investor sentiment improves as stock rises 15% Dec 20
Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking Dec 20
Investor sentiment improves as stock rises 18% Nov 30
Board Member recently bought HK$50k worth of stock Nov 29
Board Member recently bought HK$113k worth of stock Oct 31
Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock Oct 06
Investor sentiment improves as stock rises 17% Oct 05
Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock Sep 26
Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock Sep 16
Investor sentiment improves as stock rises 18% Sep 14
Price target decreased by 55% to HK$1.10 Sep 02
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023 Aug 31
First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022) Aug 31
New minor risk - Market cap size Aug 24 Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023
Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023 Aug 19
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01 May 21
Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director May 18
Upcoming dividend of HK$0.01 per share at 1.3% yield May 18
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01 Apr 02
Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021) Mar 31
Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List Jan 20
Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021) Nov 18
Price target decreased to HK$1.80 Nov 16
Less than half of directors are independent Nov 16
Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022 Nov 05
Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa Oct 27
Price target decreased to HK$1.80 Oct 11
Upcoming dividend of HK$0.01 per share Sep 01
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01 Aug 29
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022 Aug 27
Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021) Aug 27
Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022 Aug 16
Board Member recently bought HK$231k worth of stock Jul 21
Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate Jun 22
Board Member recently bought HK$381k worth of stock Jun 10
First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021) May 27
Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate May 20
Upcoming dividend of HK$0.031 per share May 19
Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022 May 17
Price target decreased to HK$4.85 Apr 27
Less than half of directors are independent Apr 27 Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022 Mar 31
Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020) Mar 30 Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022
Price target decreased to HK$5.30 Jan 19
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Nov 26
Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation Sep 29
Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020) Aug 27
Investor sentiment deteriorated over the past week Jul 27
Non-Executive Director Simon Miles Ball has left the company Jul 13
Price target decreased to HK$6.42 Jul 06
First quarter 2021 earnings released: EPS HK$0.07 (vs HK$0.068 in 1Q 2020) May 28
Price target decreased to HK$6.92 May 25
Upcoming dividend of HK$0.031 per share May 24
Lee's Pharmaceutical Holdings Limited Announces Sodium Phenylbutyrate Granules Obtained Approval for Drug Registration May 22
Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019) Apr 24
Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet? Apr 05
Full year 2020 earnings released: EPS HK$0.22 (vs HK$0.21 in FY 2019) Mar 31
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021 Mar 19
Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum? Mar 17
Investor sentiment improved over the past week Mar 16
Lee's Pharmaceutical Holdings Limited Provides Update on an Investigational Direct Oral Anticoagulant Mar 13
Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend? Feb 22
Investor sentiment improved over the past week Feb 10
New 90-day high: HK$6.01 Feb 09
What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago? Jan 29
New 90-day high: HK$5.25 Jan 21 Rendimenti per gli azionisti 950 HK Pharmaceuticals HK Mercato 7D 5.1% 0.2% 1.1% 1Y -5.2% -9.6% 17.6%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 950 ha superato il Hong Kong Pharmaceuticals che ha restituito -9.6 % nell'ultimo anno.
Rendimento vs Mercato: 950 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 17.6 % nell'ultimo anno.
Volatilità dei prezzi Is 950's price volatile compared to industry and market? 950 volatility 950 Average Weekly Movement 7.4% Pharmaceuticals Industry Average Movement 6.3% Market Average Movement 8.5% 10% most volatile stocks in HK Market 17.8% 10% least volatile stocks in HK Market 3.9%
Prezzo delle azioni stabile: 950 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di 950 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Lee's Pharmaceutical Holdings Limited, una holding di investimento, sviluppa, produce, commercializza e vende prodotti farmaceutici principalmente nella Repubblica Popolare Cinese. Si concentra su diverse aree patologiche, tra cui cardiovascolare, salute della donna, pediatria, malattie rare, oncologia, dermatologia e ostetricia. Opera attraverso i segmenti Prodotti proprietari e generici e Prodotti in licenza.
Mostra di più Lee's Pharmaceutical Holdings Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Lee's Pharmaceutical Holdings con la sua capitalizzazione di mercato? 950 statistiche fondamentali Capitalizzazione di mercato HK$853.81m Guadagni(TTM ) HK$63.06m Ricavi(TTM ) HK$1.20b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 950 Conto economico (TTM ) Ricavi HK$1.20b Costo del fatturato HK$581.63m Profitto lordo HK$617.44m Altre spese HK$554.38m Guadagni HK$63.06m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.11 Margine lordo 51.49% Margine di profitto netto 5.26% Rapporto debito/patrimonio netto 14.2%
Come si è comportato 950 nel lungo periodo?
Vedi performance storica e confronto Dividendi
2.1% Rendimento attuale del dividendo
28% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/30 05:47 Prezzo dell'azione a fine giornata 2024/12/30 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Lee's Pharmaceutical Holdings Limited è coperta da 9 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Jason Cheng 3V Capital Limited Yue-Kwong Lui BOCOM International Securities Limited Chu Wang Citigroup Inc
Mostra 6 altri analisti 
